Role of gangliosides in tumour progression: A molecular target for cancer therapy?

Medical Hypotheses

Volumn 46, Issue 2, 1996, Pages 140-144

  Fish, R G ^a  

^a Velindre NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE; GANGLIOSIDE ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CANCER THERAPY; GENE EXPRESSION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH;

EID: 0030003682     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90014-6     Document Type: Article

References (16)

1. Behan P O, Haniffah B A G. Gangliosides and neurological diseases. BMJ 1992; 305: 1309.
2. Hakomori S. Bifunctional role of glycosphingolipids. J Biol Chem 1990; 265: 18713-18716.
3. Hakomori S. Structure and function of sphingoglycolipids in transmembrane signalling and cell-cell interactions. Biochem Soc Trans 1993; 21: 583-595.
4. Baumann H, Nudelman E, Watanabe K, Hakomori S. Neutral fucolipids and fucogangliosides of rat hepatoma HTC and H35 cells, rat liver and hepatocytes. Cancer Res 1979; 39: 2637-2643.
5. Mora P T, Brady R O, Bradley R M, McFarland V W. Gangliosides in DNA virus transformed and spontaneously transformed tumorigenic mouse cell lines. Proc Natl Acad Sci USA 1969; 63: 1290-1296.
6. Nakakuma H, Sanai Y, Shiroki K, Nagai Y. Gene regulated expression of glycolipids: appearance of GD3 gangliosides on rat cells on transfection with transforming gene E1 of human adenovirus type 12 DNA and its transcriptional sub units. J Biochem 1984; 96: 1471-1480.
7. Ye J N, Gu T, Xia L, Murphy M J, Lee W, Gao N. Enhanced expression of ganglioside GD3 in human and rat hepatocellular carcinoma cells and N1H 3T3 cells transfected with human tumour DNAs. Cancer Res 1990; 50: 7697-7702.
8. Mazzoni A, Trave F, Fabbri M, Leto G, Ghidoni R. Membrane gangliosides and immuno-mediated cytolysis in drug sensitive and treatment induced multidrug resistant human ovarian cell lines. Anticancer Res 1991; 11: 2181-2185.
9. Oetteg H F. Gangliosides and Cancer. New York: VCH Publishing, 1989: 79.
10. Gottfries J, Freedman P, Mansson J E et al. Determination of gangliosides in six human primary medulloblastomas. J Neurochem 1990; 55: 1322-1326.
11. Rapelli S, Montorfano G, Gornati R, Berra B. Tissue and serum gangliosides determination in patients with meningiomas. Ital J Biochem 1989; 38: 289A-291A.
12. Sariola H, Tarava H, Rapola J, Saarinen U M. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am J Clin Pathol 1991; 96: 248-252.
13. Portoukalian J, David M J, Shen X, Richard M, Dubreuil C. Tumour size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989; 18: 759-765.
14. Ravindranath M H, Tsuchida T, Morton D, Irie R F. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991; 67: 3029-3035.
15. Valentino L, Moss T, Olsen E, Wang H J, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990; 75: 1565-1567.
16. Thampoe I J, Furukawa K, Vellve E, Lloyd K O. Sialyl-transferase levels and ganglioside expression in melanoma and other cultured human cancer cells. Cancer Res 1989; 49: 6258-6264.